avorsentan

Avorsentan (SPP 301) is a selective endothelin-A (ET-A) receptor antagonist that was developed for the treatment of diabetic nephropathy and chronic kidney disease. Originally developed by Speedel and later acquired by Novartis, the drug works by inhibiting the binding of endothelin-1 to the ET-A receptor. Endothelin-1 is a potent vasoconstrictor and pro-inflammatory peptide that plays a significant role in the progression of renal damage, including fibrosis and albuminuria. Although avorsentan demonstrated efficacy in reducing urinary albumin-to-creatinine ratios in Phase 2 and early Phase 3 trials, its development was terminated during the pivotal Phase 3 ASCEND trial. The termination was due to a significantly higher incidence of adverse events related to fluid retention, such as congestive heart failure and pulmonary edema, in patients receiving the drug compared to those receiving placebo.

Other names

avosentanRo 67-0565Ro67-0565Ro-67-0565